The new regimen improves survival in pancreatic cancer

January 3, 2018 15:32

pancreas cancer

Pancreatic cancer is difficult to treat because the tumor often does not respond to all the currently regimens. US researchers have found a new way to increase the sensitivity of cancer cells to drugs.

The results are published in the journal Nature Medicine. Researchers have found that administration of an inhibitor of focal adhesion kinase (focal adhesion kinase) mice with pancreatic cancer significantly increases tumor response to chemotherapy and immunotherapy, thereby increasing the survival of rodents.

At this stage, the study's author, David Denardo, Associate Professor of the School of Medicine at the University of Washington (USA), together with the staff plan to test the efficacy of this regimen in patients with advanced pancreatic cancer with the hope of a significant increase in survival and improving patients' quality of life.

According to the American Cancer Society, in 2016 the United States will be diagnosed about 53,070 new cases of pancreatic cancer, and more than 41 000 people die from this disease. Five-year survival rate with a low tumor and accounts for about 7.7%.

Denardo said: "It is well known that pancreatic tumors are insensitive to both standard chemotherapy regimens, and new forms of immunotherapy. We anticipate that a fibrotic microenvironment of malignant cells, typical of pancreatic cancer may be responsible for the poor response to immunotherapy is effective in other types of cancer. "

Next Denardo explains that the focal adhesion kinase plays an important role in the development of connective tissue in tumors and other diseases.

Fibrous tissue protects the cancer cells as effectively "covers" them from the immune system. This prevents the tumor cells to enter the bloodstream, which reduces their sensitivity to chemotherapy.

Based on materials http://www.medicalnewstoday.com/articles/311434.php



No comments yet

new comment


definitely (will not be published)